Qiagen stock trades around 43 dollars as investors watch margins and diagnostics demand

Published on 09/04/2026 at 18:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen stock is trading near 43 dollars on its NYSE listing as of September 3, 2026, with investors focusing on margins, molecular diagnostics demand and the company’s position in sample and assay technologies.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

Qiagen stock (ISIN NL0012169213) is trading close to 43.23 USD on its New York Stock Exchange listing as of September 3, 2026, according to a recent market overview dated September 3, 2026 that values the company at about 8.93 billion USD.

Margin profile and recent trading range

According to a market summary compiled on September 3, 2026, Qiagen shares traded at 43.23 USD in the United States, keeping the stock close to a recent trading range around the 43 dollar mark and implying a market capitalization of approximately 8.93 billion USD as of September 3, 2026.

The same overview highlights that Qiagen stock has been relatively steady in recent sessions, with the price clustering around the low 40 dollar region rather than testing its 52 week extremes, which matters for investors assessing risk versus earnings momentum.

Go deeper

More on Qiagen stock and figures

For additional figures, earnings history and more detailed corporate information on Qiagen, you can use the following overview pages.

All news on Qiagen stock Investor Relations

Sample technologies and diagnostics as growth drivers

Qiagen N.V. focuses on sample and assay technologies that are used to extract and analyze DNA, RNA and proteins, with applications in molecular diagnostics, academic research and pharmaceutical development.

For investors, demand trends in clinical diagnostics and life sciences are central, because recurring sales of consumables and test kits support margins and can stabilize earnings across different economic cycles.

Products in molecular testing

A representative product line for Qiagen in the diagnostics field is its portfolio of molecular testing kits designed for pathogen detection and oncology applications, which are used by laboratories worldwide as part of standardized workflows.

Stock price and investor perspective

Qiagen stock is quoted at 43.23 USD on the New York Stock Exchange as of September 3, 2026, leaving the shares near the 43 dollar mark that has characterized recent trading and corresponding to a market capitalization of about 8.93 billion USD at that date.